Stronger Q2 Results And Higher 2026 Guidance Might Change The Case For Investing In Omnicell (OMCL)

Simply Wall St.07-31

Omnicell, Inc. has reported past second-quarter 2026 results showing revenue of US$312.21 million and net income of US$24.29 million, alongside stronger earnings per share and improved performance for...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655038634?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","is_english":true,"pubTime":"2026-07-31 03:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655038634","market":"us","top_or_hot":-1,"title":"Stronger Q2 Results And Higher 2026 Guidance Might Change The Case For Investing In Omnicell (OMCL)","media":"Simply Wall St.","content":"<div>\n<p>Omnicell, Inc. has reported past second-quarter 2026 results showing revenue of US$312.21 million and net income of US$24.29 million, alongside stronger earnings per share and improved performance for...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/stronger-q2-results-and-higher-2026-guidance-might-change-th\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stronger Q2 Results And Higher 2026 Guidance Might Change The Case For Investing In Omnicell (OMCL)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStronger Q2 Results And Higher 2026 Guidance Might Change The Case For Investing In Omnicell (OMCL)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-31 03:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/stronger-q2-results-and-higher-2026-guidance-might-change-th><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Omnicell, Inc. has reported past second-quarter 2026 results showing revenue of US$312.21 million and net income of US$24.29 million, alongside stronger earnings per share and improved performance for...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/stronger-q2-results-and-higher-2026-guidance-might-change-th\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CHAT","symbol_name":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/stronger-q2-results-and-higher-2026-guidance-might-change-th","article_id":"2655038634","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/stronger-q2-results-and-higher-2026-guidance-might-change-th","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2655038634","pubTimestamp":1785439300,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Omnicell, Inc. has reported past second-quarter 2026 results showing revenue of US$312.21 million and net income of US$24.29 million, alongside stronger earnings per share and improved performance for the first half of the year compared with the prior period.\nThe company also issued revenue guidance of US$301 million–US$307 million for the third quarter and US$1.23 billion–US$1.25 billion for full-year 2026, giving investors clearer visibility into its near-term growth trajectory.\nWith...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4082":"医疗保健设备","BK4167":"医疗保健技术","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","VTHR":"Vanguard Russell 3000 ETF","RGLO":"Global Equity Active ETF","PMDE":"PGIM S&P 500 Max Buffer ETF - December","AIPO":"Defiance AI and Power Infrastructure ETF","VOTE":"TCW Transform 500 ETF","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","GXDW":"Global X Dorsey Wright Thematic ETF","JOYT":"JPMorgan Equity and Options Total Return ETF","OMCL":"Omnicell","VGFPF":"Vanguard Funds PLC","QTOC":"Innovator Growth Accelerated Plus ETF - October","AGIX":"通用人工智能 ETF-AGIX"},"translate_title":"强劲的第二季度业绩和更高的 2026 年指引可能会改变投资 Omnicell (OMCL) 的情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARTY":0.62,"JOYT":0.73,"QTOC":0.62,"VOTE":0.73,"AGIX":0.62,"FEBU":0.73,"GXDW":0.73,"OMCL":1.5,"RGLO":0.83,"AIPO":0.73,"PMDE":0.73,"VTHR":0.62,"VGFPF":0.73,"DECU":0.73,"CHAT":0.62},"content_text":"Omnicell, Inc. has reported past second-quarter 2026 results showing revenue of US$312.21 million and net income of US$24.29 million, alongside stronger earnings per share and improved performance for the first half of the year compared with the prior period. The company also issued revenue guidance of US$301 million–US$307 million for the third quarter and US$1.23 billion–US$1.25 billion for full-year 2026, giving investors clearer visibility into its near-term growth trajectory. With Omnicell’s updated full-year 2026 revenue guidance now set above US$1.22 billion, we’ll examine how this reshapes its investment narrative. This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.AdvertisementOmnicell Investment Narrative RecapTo own Omnicell, you need to believe that hospitals and health systems will keep investing in medication automation and that Omnicell can turn that demand into improving profitability. The latest second quarter beat and higher full year 2026 revenue guidance help the near term earnings story, but they do not remove key risks around tariff costs and potential pressure on hospital capital budgets. The most relevant recent announcement is the updated 2026 revenue outlook of US$1.225 billion to US$1.245 billion, coming alongside stronger first half earnings. This tighter, slightly higher range gives you more concrete near term benchmarks against which to judge whether Omnicell is making progress on its shift toward more recurring revenue and better margins, or whether competitive and macro pressures are still the more important forces. Yet beneath the improved guidance, investors should still be aware of the risk that hospital budget constraints could... Read the full narrative on Omnicell (it's free!)Omnicell's narrative projects $1.4 billion revenue and $71.2 million earnings by 2029. This requires 4.4% yearly revenue growth and about a $50.8 million earnings increase from $20.4 million today.Uncover how Omnicell's forecasts yield a $61.29 fair value, a 48% upside to its current price.Exploring Other PerspectivesOMCL 1-Year Stock Price Chart Before this earnings beat, the most optimistic analysts were already assuming Omnicell could reach about US$1.4 billion of revenue and US$83 million of earnings by 2029, which is a much more upbeat view than caution around slower OmniSphere adoption suggests, and this new information may push some of those expectations in either direction as you compare these very different stories.Explore 4 other fair value estimates on Omnicell - why the stock might be worth just $60.12!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Omnicell research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Omnicell research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Omnicell's overall financial health at a glance.Ready To Venture Into Other Investment Styles?Our top stock finds are flying under the radar-for now. Get in early:Uncover the next big thing with 20 elite penny stocks that balance risk and reward.Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655038634","isCrawlerRequest":true}